Showing results (11-20 of 492) with videos related to
Sort By:
Pageof 50
Blood|July 29, 2011
Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)Sham Mailankody, Ruth M Pfeiffer, Sigurdur Y Kristinsson, et al.Cancer Chemotherapy and Pharmacology|May 11, 2017
Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphismsTristan M Sissung, Cody J Peer, Neha Korde, et al.JAMA Oncology|July 17, 2015
The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple MyelomaElin Edda Sigurdardottir, Ingemar Turesson, Sigrun Helga Lund, et al.JAMA Internal Medicine|September 12, 2017
Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After ApprovalVinay Prasad, Sham MailankodySeminars in Oncology|February 6, 2022
"Off-the-shelf" immunotherapies for multiple myelomaTurab Mohammed, Sham MailankodySeminars in Hematology|May 16, 2018
MRD Testing in Multiple Myeloma: From a Surrogate Marker of Clinical Outcomes to an Every-Day Clinical ToolOla LandgrenHematology. American Society of Hematology. Education Program|December 10, 2013
Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategiesOla LandgrenLeukemia|May 5, 2026
Smoldering multiple myeloma in transition: redefining early myeloma in the modern eraOla LandgrenHematology. American Society of Hematology. Education Program|December 10, 2017
Shall we treat smoldering multiple myeloma in the near future?Ola LandgrenPageof 50